Centessa reports Q4 net loss $36.8M; cash $256.5M; SerpinPC and ORX750 milestones on track

Centessa Pharmaceuticals plc

Net loss of $36.8M for Q4 2023 vs $43.2M YoY; full-year net loss $151.1M vs $216.2M.
Cash, equivalents and ST investments $256.5M at Dec 31, 2023; plus $9.7M ATM proceeds in Jan 2024; funding into 2026.
SerpinPC PRESent-2 Part 1 interim analysis planned in 2024; Part 1 data at medical conference late 2024/early 2025.
ORX750 IND clearance targeted; clinical proof-of-concept data in sleep-deprived healthy volunteers expected in 2024.
Phase 2a SerpinPC data showed 96% median all-bleed ABR reduction with no thromboembolic events to date.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Centessa Pharmaceuticals plc reported financial results for the fourth quarter and full-year ended December 31, 2023.

Period: the fourth quarter and full-year ended December 31, 2023
Result: reported results

Exact text from the filing

Centessa Pharmaceuticals plc (the "Company") announced its financial results for the quarter ended December 31, 2023.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Centessa Pharmaceuticals plc filing history →

Source: SEC EDGAR

accession 0001847903-24-000052

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.